History

Enclomiphene was developed by Repros Therapeutics under the tentative brand names Androxal (US) and EnCyzix (EU) for secondary (hypogonadotropic) hypogonadism in men who wished to preserve fertility. It was never approved: the FDA issued a Complete Response Letter in late 2015, viewing the Phase 3 trial designs and results as inadequate to establish clinical benefit (testosterone rose, but the clinical relevance of that biomarker improvement was not convincingly shown) and asking for additional work, and the EU CHMP recommended refusal of marketing authorization in January 2018. Repros discontinued enclomiphene development in 2021. Clomiphene itself remains FDA-approved — but only for ovulation induction in women, never for men.

Enclomiphene gets passed around fitness and “research chemical” circles as if it were a peptide or a sleek next-generation drug. It is neither. It is one of the two isomers of clomiphene — the anti-estrogenic half — and it is a small-molecule oral selective estrogen receptor modulator (SERM) in the same chemical family as tamoxifen. The single most important fact about it is regulatory: despite years of development and real human trial data, it is not FDA-approved for anything. This page is educational and harm-reduction oriented; it contains no dosing, cycles, stacks, or post-cycle protocols, and no sourcing information.

What it is

Enclomiphene (INN: enclomifene) is the (E)-/trans-stereoisomer of clomiphene. Clomiphene citrate (Clomid) is not a single molecule but a roughly 62:38 mixture of enclomiphene — the antiestrogenic isomer — and zuclomifene, the longer-acting, estrogenic Z-isomer. Enclomiphene is the “active anti-estrogen” fraction isolated out on its own.

As a class, it is an oral, nonsteroidal SERM that acts as an estrogen-receptor antagonist at the hypothalamus and pituitary. Mechanistically, by blocking estrogen-mediated negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis, it increases GnRH, which drives up pituitary LH and FSH, which in turn raises endogenous testicular testosterone while preserving or stimulating FSH-driven spermatogenesis. This is “restoration” of a man’s own axis — the deliberate contrast with exogenous testosterone (TRT), which suppresses LH, FSH, and spermatogenesis. Its serum half-life is short (about 10 hours, with a peak around 2-3 hours), but a “legacy” elevation of testosterone and LH lasting at least about a week after stopping has been observed.

The claims

The intended medical claim was narrow and specific: men with low testosterone plus low or inappropriately-normal LH — secondary (hypogonadotropic) hypogonadism — who want to preserve fertility and testicular volume, especially younger men or those planning children. The pitch was that enclomiphene could raise a man’s own testosterone without the fertility-suppressing downside of TRT.

In the athletics and bodybuilding context, SERMs like enclomiphene, clomiphene, and tamoxifen are used by anabolic-androgenic steroid (AAS) users to attempt to restart endogenous testosterone after a steroid cycle (“post-cycle”) by stimulating LH and FSH, and to counter estrogenic side effects. Per the constraints of this page, no doses, cycles, stacks, or PCT protocols are provided.

What the evidence actually shows

The strongest data come from the Repros (Wiehle/Kim) trials in secondary hypogonadism, and they are reasonably consistent on the hormonal endpoints:

It consistently raises total testosterone into the eugonadal (normal) range, comparable to topical testosterone gels, with lower variability.
It raises LH and FSH — where TRT suppresses them — and preserves or maintains sperm concentration and testicular volume. That fertility-preservation contrast with TRT is the entire reason it draws interest.

What it has not proven is the part that matters for approval: durable, FDA-grade clinical or symptomatic benefit (libido, energy, body composition) or hard fertility outcomes such as live births. The trials measured hormones and sperm counts, not pregnancies or long-term outcomes, and long-term safety data are limited. This is precisely the gap the FDA flagged — the biomarker moved, but the clinical relevance in the target population was not convincingly established. That is why this profile is graded Preliminary human rather than “Strong human”: the hormonal evidence is solid, but the drug never cleared the bar for proven clinical benefit, and it remains unapproved.

Legal and regulatory status

In the United States, enclomiphene is an Rx-only investigational drug that is not FDA-approved for any use. It is legal only when prescribed off-label by a physician and compounded by a state-licensed pharmacy (503A/503B); it is not an OTC product and not a finished FDA-approved drug. It is illegal to sell as a dietary supplement or “research chemical” — it appears on the US Department of Defense Prohibited Dietary Supplement Ingredients List (per Operation Supplement Safety). It is not a controlled substance.

For legal context among the compounds that come up alongside it:

Clomiphene is an FDA-approved prescription drug — but only for ovulation induction in women. It is not FDA-approved for men, where all use (like essentially all enclomiphene use) is off-label or via compounding. Not a controlled substance.
DNP (2,4-dinitrophenol) is NOT approved for human consumption. It was effectively removed as a weight-loss drug around the time of the 1938 Federal Food, Drug, and Cosmetic Act after deaths and cataracts, and is now sold illegally online as a “fat burner.” It has a long, documented history of fatal poisonings.
Mesterolone (Proviron) and fluoxymesterone (Halotestin) are anabolic-androgenic steroids and Schedule III controlled substances under the US Controlled Substances Act (Anabolic Steroids Control Act of 1990, Pub. L. 101-647).

Safety

Enclomiphene / SERMs (class risks). Short-term, SERMs are generally well tolerated; common adverse events in trials include headache and mild mood or visual symptoms, and a modest IGF-1 decrease was noted. The class-level concerns are real, though:

Thromboembolism (VTE / DVT / PE) is a recognized SERM-class concern — well established for tamoxifen.
Visual disturbances (blurring, light flashes, and rarely central retinal vein occlusion or optic neuropathy) are documented with clomiphene.
Long-term safety of enclomiphene specifically is not established — there is no approval and limited long-term data. And because the mechanism works by suppressing estrogen signaling, over-suppression of estrogen can adversely affect mood, libido, lipids, and bone over time.

Aromatase inhibitors (AIs), which come up in the same conversations, lower estradiol directly and can cause bone loss/osteoporosis, adverse lipid changes, joint pain/arthralgia, and libido or mood effects. In men, crashing estrogen too low is itself harmful.

DNP — the most dangerous compound here, and it kills people. It is a mitochondrial uncoupler that causes uncontrolled hyperthermia (core temperatures up to roughly 44 °C / 111 °F), tachycardia, severe metabolic and respiratory acidosis, multi-organ failure, and death — sometimes within hours. There is NO specific antidote; treatment is only supportive (aggressive cooling and fluids). The margin between an “effective” and a lethal amount is dangerously narrow, numerous deaths have been reported, and there is no safe human dose.

Insulin (non-diabetic / PED misuse). Can cause severe, lethal hypoglycemia — confusion, seizures, coma, permanent brain injury, death. The risk is acute and unforgiving.

Thyroid hormone (T3 / liothyronine) misuse for fat loss risks cardiac arrhythmia, tachycardia, atrial fibrillation, and ischemia, muscle catabolism, and suppression of the endogenous thyroid axis (potential rebound hypothyroidism after stopping).

Anabolic steroids (mesterolone, fluoxymesterone): hepatotoxicity (especially oral 17α-alkylated agents like fluoxymesterone), adverse lipids and cardiovascular risk, HPG-axis suppression and infertility, gynecomastia, mood and aggression effects, and virilization.

None of this is medical advice.

Bottom line

Enclomiphene is a SERM — the anti-estrogenic isomer of clomiphene — not a peptide and not a steroid. Human trials consistently show it raises testosterone, LH, and FSH and preserves spermatogenesis and testicular volume, which is a genuine, meaningful contrast with testosterone replacement. But it is not FDA-approved for any use: the FDA issued a Complete Response Letter in 2015 because the clinical benefit behind the hormone numbers was never convincingly shown, the EU recommended refusal in 2018, and the developer discontinued it in 2021. Today it exists only as an off-label, compounded, investigational drug — not a controlled substance, but illegal to sell as a supplement or “research chemical.” In sport it is banned at all times. The hormonal data are real; the proven clinical benefit and the approval are not.

Evidence grade: Preliminary human. Consistent human trial evidence that it raises testosterone while preserving fertility markers, but no proven durable clinical or fertility outcomes, no FDA approval, and limited long-term safety data.